Pluristem Of Israel Joins U.S., Europe Trials Of Placenta Cells
This article was originally published in PharmAsia News
Executive Summary
Israel's Pluristem Therapeutics says it has qualified as an advisor to the U.S. FDA and the European Medicines Agency for trials of the PLS-PAD cell therapy for blocked arteries